Anlotinib for recurrent craniopharyngioma
Treatments studied
Part of Cancer clinical trials.
This trial tests if the drug anlotinib can safely and effectively treat recurrent craniopharyngioma, a type of brain tumor. It is for patients whose tumor has come back or grown after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a craniopharyngioma that has come back or grown after treatment
- Your tumor is mainly fluid-filled (cystic) or solid
- Your tumor is measurable on scans
- You are in generally good health, with a performance score of at least 70
- Your liver, kidney, and blood tests are within normal limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking anlotinib (a targeted therapy that may help stop cancer growth) after first-line treatment reduces the chance of rhabdomyosarcoma coming back in children with high-risk or intermediate-risk disease. Your child may be eligible if they've achieved complete remission and meet specific health and lab criteria.
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
This trial tests a targeted therapy pill (anlotinib) for people with advanced thyroid cancer that stopped responding to radioactive iodine. It may slow tumor growth or shrink tumors.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This trial tests whether adding anlotinib (a targeted therapy) to standard radiation can better control breast cancer that has spread to the brain. It is for people with HER2-negative breast cancer and at least one brain tumor seen on MRI.
Hear when a new Craniopharyngiomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.